三元生物涨0.11%，成交额2849.74万元，近3日主力净流入67.00万

Core Viewpoint - The company, Shandong Sanyuan Biotechnology Co., Ltd., is engaged in the research, production, and sales of erythritol and its compound products, benefiting from trends in sugar alternatives, synthetic biology, and green energy [2][7]. Group 1: Company Overview - The main products of the company include erythritol and compound sugars, with a revenue composition of 88.22% from sugar alcohols, 8.59% from functional sugars, 2.93% from other categories, and 0.26% from glycosides [7]. - The company was established on January 26, 2007, and went public on February 10, 2022 [7]. - As of November 20, the number of shareholders increased by 5.13% to 16,300, with an average of 7,977 circulating shares per person, a decrease of 4.88% [7]. Group 2: Financial Performance - For the period from January to September 2025, the company reported a revenue of 476 million yuan, a year-on-year decrease of 7.54%, and a net profit attributable to shareholders of 67.4 million yuan, down 16.80% year-on-year [7]. - The company has distributed a total of 608 million yuan in dividends since its A-share listing, with 473 million yuan distributed over the past three years [8]. Group 3: Market Position and Recognition - The company has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, which is a prestigious title in China for companies excelling in niche markets and possessing strong innovation capabilities [2]. - The company benefits from a significant overseas revenue share of 69.27%, aided by the depreciation of the Chinese yuan [3]. Group 4: Recent Market Activity - On November 28, the company's stock price increased by 0.11%, with a trading volume of 28.5 million yuan and a turnover rate of 0.79%, resulting in a total market capitalization of 5.59 billion yuan [1]. - The stock's average trading cost is 29.43 yuan, with the current price near a support level of 27.27 yuan [6].